Capital Royalty launches $805M fund for biotech, healthcare deals

Houston-based Capital Royalty has pieced together an $805 million fund to back a new package of loans and royalty deals with biotechs, pharma and other healthcare companies looking for some "alternative" sources of financing. Founded by former Hicks, Muse, Tate & Furst partner Charles Tate 10 years ago, fund managers plan to look for investments ranging from $20 million to $200 million. "The high level of investor demand for this fund reflects Capital Royalty's consistent performance and differentiated investment strategy," said Tate in a statement. Release